Point-of-care supply: know the environment behind the buy.

Point-of-care media includes different environments, from screens in clinical settings to professional reference tools and placements within electronic health record workflows. Their audiences, context, identity methods, and measurement capabilities are not interchangeable. A clinical setting alone does not establish individual HCP verification.

Map ownership and access separately.

For every proposed placement, identify the environment, inventory owner, direct seller or reseller, and the contractual route available to the brand. Confirm the current relationship with the relevant parties. Access to an environment does not necessarily mean ownership, exclusivity, or access to every clinician using it.

Where sellers offer access to the same environment, investigate whether the proposed placements and audiences overlap. Shared supply is a reason to examine incremental value, not proof that every exposure is duplicated. Repetition can have a role when it is intentional and measured appropriately.

Test the audience and workflow fit.

Ask what authentication means for the specific placement: a verified professional account, an inferred identity, an institution, or an audience estimate. Check specialty, treatment setting, geography, content eligibility, and the point in the workflow where the message can appear. Request evidence against the intended audience rather than relying on a platform-wide reach total.

For a named-account launch, assess coverage of the relevant institutions and decision roles. A second supply path may reach a different role or setting within an account. Its value depends on those differences, cost, and the objective, not simply whether the institution already appears in another report.

Compare paths on consistent terms.

Use the same criteria for audience evidence, context, content constraints, cost, minimum commitment, reporting access, and operational fit. Record ownership and reseller dependencies. Compare overlap only where compatible data and permissions allow it; otherwise state the uncertainty and avoid summing unique reach claims.

Partner expertise helps explain inventory and implementation. Independent review brings a common evaluation framework and documented rationale across those options. Neither role substitutes for evidence about the actual proposed placements.

Make the limits part of the recommendation.

A useful supply review provides a map, partner scorecard, observed or estimated overlap, unresolved questions, and recommended next steps. Financial exposure is estimated only where delivery and cost evidence supports it. The output should distinguish verified findings from seller claims and should never promise universally deduplicated reach.